Grandfield & Dodd LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 14.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 172,025 shares of the biopharmaceutical company’s stock after selling 28,306 shares during the quarter. Grandfield & Dodd LLC’s holdings in Gilead Sciences were worth $21,114,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in shares of Gilead Sciences by 52.1% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after purchasing an additional 26,882 shares in the last quarter. Cookson Peirce & Co. Inc. increased its stake in shares of Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after purchasing an additional 7,168 shares in the last quarter. NewEdge Wealth LLC increased its stake in shares of Gilead Sciences by 2.9% in the third quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock worth $75,962,000 after purchasing an additional 17,284 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of Gilead Sciences by 16.5% in the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after purchasing an additional 726,101 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Gilead Sciences by 4.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 161,155 shares of the biopharmaceutical company’s stock worth $17,888,000 after purchasing an additional 6,680 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on GILD shares. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Truist Financial reaffirmed a “buy” rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Leerink Partners cut their target price on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Wolfe Research raised their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.
Gilead Sciences Price Performance
GILD stock opened at $134.43 on Friday. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a fifty day simple moving average of $135.30 and a two-hundred day simple moving average of $134.09. The firm has a market capitalization of $166.90 billion, a P/E ratio of 18.31 and a beta of 0.31.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the business earned $1.81 earnings per share. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 53,000 shares of company stock worth $7,075,670 over the last 90 days. 0.30% of the stock is owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Stories
- Five stocks we like better than Gilead Sciences
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
